Erratum: Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide population-based cohort study (BMJ Open (2017) 7 (e014571) DOI: 10.1136/bmjopen-2016-014571);Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide population-based cohort study

BMJ Open

Volumn 7, Issue 1, 2017, Pages

  Tsai, Tzung Yi ^a,b,c   Livneh, Hanoch ^d   Hung, Tsung Hsing ^a,e   Lin, I Hsin ^f   Lu, Ming Chi ^a,e   Yeh, Chia Chou ^a,f  

^a DALIN TZU CHI HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^d PORTLAND STATE UNIVERSITY   (United States)

^e Institute of Clinical Medicine and Cardiovascular Research Institute   (Taiwan)

^f TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; BAI HUA SHE SHE CAO; BAN LAN GEN; BAN ZHI LIAN; CHAI HU CHING KAN TANG; CHAI HU SHU GAN TANG; ENTECAVIR; GAN LU HSIAO TU TAN; GAN LU YIN; HAI PIAO XIAO; HERBACEOUS AGENT; HU ZHANG; JIA WEI XIAO YAO SAN; LAMIVUDINE; LONG DAN XIE GAN TANG; PRESCRIPTION DRUG; SHAN ZHA; SHENG DI HUANG; TELBIVUDINE; TENOFOVIR; TIAN HUA FEN; UNCLASSIFIED DRUG; WU LING SAN; XIANG FU; XIAO CHAI HU TANG; YI GUAN JIAN; YIN CHEN HAO; YIN CHEN WU LIN SAN;

ADULT; ANTIVIRAL THERAPY; ARTEMISIA CAPILLARIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CHINESE HERB; CHINESE MEDICINE; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONTROLLED STUDY; CRATAEGI FRUCTUS; CRATAEGUS; CROSS-SECTIONAL STUDY; CYPERUS ROTUNDUS; DRUG EFFICACY; ENDOCONCHA SEPIAE; FEMALE; FOLLOW UP; HEDYOTIS; HEDYOTIS DIFFUSA; HERBAL MEDICINE; HUMAN; ISATIS; ISATIS TINCTORIA; LIVER CELL CARCINOMA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; OBSERVATIONAL STUDY; POLYGONUM CUSPIDATUM; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; REHMANNIA GLUTINOSA; RETROSPECTIVE STUDY; RISK REDUCTION; SCUTELLARIA BARBATA; TRICHOSANTHIS KIRILOWII; FACTUAL DATABASE; LIVER TUMOR; PROTECTION; RISK FACTOR; TAIWAN;

ADULT; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DATABASES, FACTUAL; DRUGS, CHINESE HERBAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTECTIVE FACTORS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 85010747933     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-014571corr1     Document Type: Erratum

References (52)

1. Qi FH, Wang ZX, Cai PP, et al. Traditional Chinese medicine and related active compounds: a review of their role on hepatitis B virus infection. Drug Discov Ther 2013; 7: 212-24
2. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011; 26(Suppl 1): 138-43
3. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31
4. Chang TT, Liaw YF, Wu SS, et al. Long-Term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93
5. Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-Analysis. J Natl Cancer Inst 2009; 101: 1066-82
6. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92
7. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-38
8. Nahin RL, Barnes PM, Stussman BJ, et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report 2009; 30: 1-14
9. Dobos GJ, Tan L, Cohen MH, et al. Are national quality standards for traditional Chinese herbal medicine sufficient?. Current governmental regulations for traditional Chinese herbal medicine in certain Western countries and China as the Eastern origin country. Complement Ther Med 2005; 13: 183-90
10. McCulloch M, Broffman M, Gao J, et al. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-Analysis of randomized, controlled trials. Am J Public Health 2002; 92: 1619-28
11. Liao YH, Lin CC, Li TC, et al. Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan. BMC Complement Altern Med 2012; 12: 146
12. Zhang L, Wang G, Hou W, et al. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology 2010; 51: 690-8
13. Qu J, Yu Z, Li Q, et al. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials 2014; 15: 438
14. Shen WS, Yang HZ, Hong Q, et al. Two-year observation of the clinical efficacy in treating chronic hepatitis B Patients with Ganxian recipe and lamivudine. Chin J Integr Med 2005; 11: 5-10
15. Liao YH, Lin CC, Lai HC, et al. Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients. Liver Int 2015; 35: 2595-602
16. Cui X, Wang Y, Kokudo N, et al. Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 2010; 4: 39-47
17. National Health Insurance Research Database, Taiwan. http: //nhird. nhri.org.tw/date-cohort.html (accessed May 2016).
18. Tsai TY, Li CY, Livneh H, et al. Decreased risk of stroke in patients receiving traditional Chinese medicine for vertigo: a population-based cohort study. J Ethnopharmacol 2016; 184: 138-43
19. Shariff SZ, Cuerden MS, Jain AK, et al. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008; 19: 841-3
20. Liu CY, Hung YT, Chuang Y, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006; 4: 1-22
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-19
22. Burstein HJ, Gelber S, Guadagnoli E, et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999; 340: 1733-9
23. Hung YC, Hung IL, Sun MF, et al. Integrated traditional Chinese medicine for childhood asthma in Taiwan: a nationwide cohort study. BMC Complement Altern Med 2014; 14: 389
24. Blanc PD, Trupin L, Earnest G, et al. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest 2001; 120: 1461-7
25. Liao HH, Yeh CC, Lin CC, et al. Prescription patterns of Chinese herbal products for patients with fractures in Taiwan: a nationwide population-based study. J Ethnopharmacol 2015; 173: 11-19
26. Lin YH, Chen KK, Chiu JH. Use of Chinese medicine among prostate cancer patients in Taiwan: a retrospective longitudinal cohort study. Int J Urol 2011; 18: 383-6
27. Liaw YF. Impact of hepatitis B therapy on the long-Term outcome of liver disease. Liver Int 2011; 31(Suppl 1): 117-21
28. Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014; 147: 143-51
29. Wu L, Li H, Zheng SZ, et al. Da-Huang-Fu-Zi-Tang attenuates liver injury in rats with severe acute pancreatitis. J Ethnopharmacol 2013; 150: 960-6
30. Meng MB, Wen QL, Cui YL, et al. Meta-Analysis: traditional Chinese medicine for improving immune response in patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Explore (NY) 2011; 7: 37-43
31. Chen QL, Lu YY, Peng JH, et al. Dynamical regulation analysis identifies molecular mechanisms of Fuzheng-Huayu formula against hepatitis B-caused liver cirrhosis. Evid Based Complement Alternat Med 2015; 2015: 238495
32. Teng L, Zhang J, Dai M, et al. Correlation between traditional Chinese medicine symptom patterns and serum concentration of zinc, iron, copper and magnesium in patients with hepatitis B and associated liver cirrhosis. J Tradit Chin Med 2015; 35: 546-50
33. Cromlish JA. Hepatitis B virus-induced hepatocellular carcinoma: possible roles for HBx. Trends Microbiol 1996; 4: 270-4
34. Kim CM, Koike K, Saito I, et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-20
35. Su Q, Schröder CH, Hofmann WJ, et al. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology 1998; 27: 1109-20
36. Lin HJ, Kao ST, Siao YM, et al. The Chinese medicine sini-san inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells. BMC Complement Altern 2015; 15: 348
37. Su YC, Lin IH, Siao YM, et al. Modulation of the tumor metastatic microenvironment and multiple signal pathways by prunella vulgaris in human hepatocellular carcinoma. Am J Chin 2016; 44: 835-49
38. Hu B, Wang SS, Du Q. Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: from bench to bedside. World J Hepatol 2015; 7: 1209-32
39. Yu JH, Shi JP, Wu J, et al. [Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi 2011; 19: 88-92
40. Chen T, Chen WH. [Advances of combined treatment for chronic hepatitis B with lamivudine]. Zhong Xi Yi Jie He Xue Bao 2003; 1: 146-50
41. Feng H, Zhang YH. Effect of Chinese medicine therapy for strengthening-pi and nourishing-shen in preventing lamivudine induced YMDD mutation and its immunologic mechanism. Chin J Integr Med 2010; 16: 19-22
42. Lee HZ, Bau DT, Kuo CL, et al. Clarification of the phenotypic characteristics and anti-Tumor activity of hedyotis diffusa. Am J Chin Med 2011; 39: 201-13
43. Chen XZ, Cao ZY, Chen TS, et al. Water extract of hedyotis diffusa willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway. Oncol Rep 2012; 28: 742-8
44. Chan JY, Tang PM, Hon PM, et al. Pheophorbide a, a major antitumor component purified from scutellaria barbata, induces apoptosis in human hepatocellular carcinoma cells. Planta Med 2006; 72: 28-33
45. Juan M, Minhu C, Yun D, et al. Enhancing the efficacy of photodynamic therapy by a Chinese herbal medicine for hepatocellular carcinoma. Cancer Biol Ther 2006; 5: 1117-19
46. Chao JC, Chiang SW, Wang CC, et al. Hot water-extracted Lycium barbarum and rehmannia glutinosa inhibit proliferation and induce apoptosis of hepatocellular carcinoma cells. World J Gastroenterol 2006; 12: 4478-84
47. Du H, Zhang S, Song M, et al. Assessment of a flavonepolysaccharide based prescription for treating duck virus hepatitis. PLoS ONE 2016; 11: e0146046
48. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-To (TJ-9). Cancer 1995; 76: 743-9
49. Lee JK, Kim JH, Shin HK. Therapeutic effects of the oriental herbal medicine sho-saiko-To on liver cirrhosis and carcinoma. Hepatol Res 2011; 41: 825-37
50. Rino Y, Yukawa N, Yamamoto N. Does herbal medicine reduce the risk of hepatocellular carcinoma?. World J Gastroenterol 2015; 21: 10598-603
51. Hu JH, Chen MY, Yeh CT, et al. Sexual dimorphic metabolic alterations in hepatitis C virus-infected patients: a community-based study in a hepatitis B/hepatitis C virus hyperendemic area. Medicine (Baltimore) 2016; 95: e3546
52. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102: 179-86